Logo image of GTBP

GT BIOPHARMA INC (GTBP) Stock Fundamental Analysis

NASDAQ:GTBP - Nasdaq - US36254L3087 - Common Stock - Currency: USD

2.27  +0.07 (+3.18%)

Fundamental Rating

2

Taking everything into account, GTBP scores 2 out of 10 in our fundamental rating. GTBP was compared to 572 industry peers in the Biotechnology industry. GTBP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GTBP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GTBP has reported negative net income.
In the past year GTBP has reported a negative cash flow from operations.
In the past 5 years GTBP always reported negative net income.
GTBP had a negative operating cash flow in each of the past 5 years.
GTBP Yearly Net Income VS EBIT VS OCF VS FCFGTBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M -200M -250M

1.2 Ratios

GTBP has a Return On Assets of -97.22%. This is in the lower half of the industry: GTBP underperforms 74.69% of its industry peers.
GTBP has a Return On Equity of -181.40%. This is in the lower half of the industry: GTBP underperforms 67.61% of its industry peers.
Industry RankSector Rank
ROA -97.22%
ROE -181.4%
ROIC N/A
ROA(3y)-119.66%
ROA(5y)-2123.63%
ROE(3y)-181.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GTBP Yearly ROA, ROE, ROICGTBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20K -20K

1.3 Margins

GTBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GTBP Yearly Profit, Operating, Gross MarginsGTBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for GTBP has been increased compared to 1 year ago.
GTBP has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GTBP Yearly Shares OutstandingGTBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
GTBP Yearly Total Debt VS Total AssetsGTBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

GTBP has an Altman-Z score of -99.69. This is a bad value and indicates that GTBP is not financially healthy and even has some risk of bankruptcy.
GTBP's Altman-Z score of -99.69 is on the low side compared to the rest of the industry. GTBP is outperformed by 97.35% of its industry peers.
There is no outstanding debt for GTBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -99.69
ROIC/WACCN/A
WACCN/A
GTBP Yearly LT Debt VS Equity VS FCFGTBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

A Current Ratio of 2.15 indicates that GTBP has no problem at all paying its short term obligations.
The Current ratio of GTBP (2.15) is worse than 74.87% of its industry peers.
GTBP has a Quick Ratio of 2.15. This indicates that GTBP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of GTBP (2.15) is worse than 73.45% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 2.15
GTBP Yearly Current Assets VS Current LiabilitesGTBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

GTBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.40%, which is quite impressive.
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-446.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GTBP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.60% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GTBP Yearly Revenue VS EstimatesGTBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20B 40B 60B 80B
GTBP Yearly EPS VS EstimatesGTBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GTBP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GTBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GTBP Price Earnings VS Forward Price EarningsGTBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GTBP Per share dataGTBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

A more expensive valuation may be justified as GTBP's earnings are expected to grow with 19.48% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.6%
EPS Next 3Y19.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GTBP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GT BIOPHARMA INC

NASDAQ:GTBP (2/5/2025, 8:04:02 PM)

2.27

+0.07 (+3.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners60.11%
Inst Owner Change0.14%
Ins Owners1.8%
Ins Owner Change0%
Market Cap5.06M
Analysts82.86
Price Target11.22 (394.27%)
Short Float %9.54%
Short Ratio0.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.46%
Min EPS beat(2)20.48%
Max EPS beat(2)40.45%
EPS beat(4)4
Avg EPS beat(4)38.27%
Min EPS beat(4)20.48%
Max EPS beat(4)50.98%
EPS beat(8)6
Avg EPS beat(8)24.17%
EPS beat(12)9
Avg EPS beat(12)13.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-92.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)37.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.95
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-7.13
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-4.53
FCFYN/A
OCF(TTM)-4.53
OCFYN/A
SpS0
BVpS2.38
TBVpS2.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.22%
ROE -181.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.66%
ROA(5y)-2123.63%
ROE(3y)-181.46%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 2.15
Altman-Z -99.69
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-446.67%
EPS Next Y-19.62%
EPS Next 2Y27.6%
EPS Next 3Y19.48%
EPS Next 5Y12.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y33.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-102023%
EBIT Next 3Y-912.25%
EBIT Next 5YN/A
FCF growth 1Y41.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.01%
OCF growth 3YN/A
OCF growth 5YN/A